Xenon Pharmaceuticals
Market Cap
US$452.6m
Last Updated
2020/07/02 00:06 UTC
Data Sources
Company Financials +
Executive Summary
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada.
Rewards
Risk Analysis
Earnings are forecast to decline by an average of -18.5% per year for the next 3 years
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Excellent balance sheet with limited growth.
Share Price & News
How has Xenon Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: XENE has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
-0.7%
XENE
1.4%
US Biotechs
1.9%
US Market
1 Year Return
28.8%
XENE
22.0%
US Biotechs
4.3%
US Market
Return vs Industry: XENE exceeded the US Biotechs industry which returned 22% over the past year.
Return vs Market: XENE exceeded the US Market which returned 4.3% over the past year.
Shareholder returns
| XENE | Industry | Market | |
|---|---|---|---|
| 7 Day | -0.7% | 1.4% | 1.9% |
| 30 Day | 0.2% | 4.9% | 2.7% |
| 90 Day | 22.5% | 29.6% | 26.4% |
| 1 Year | 28.8%28.8% | 23.2%22.0% | 6.5%4.3% |
| 3 Year | 298.2%298.2% | 30.7%26.4% | 35.1%26.2% |
| 5 Year | 30.9%30.9% | 1.8%-4.2% | 67.0%48.4% |
Price Volatility Vs. Market
How volatile is Xenon Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 weeks ago | Simply Wall St
Don't Ignore The Fact That This Insider Just Sold Some Shares In Xenon Pharmaceuticals Inc. (NASDAQ:XENE)1 month ago | Simply Wall St
New Forecasts: Here's What Analysts Think The Future Holds For Xenon Pharmaceuticals Inc. (NASDAQ:XENE)1 month ago | Simply Wall St
Do Directors Own Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares?Valuation
Is Xenon Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
2.51x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate XENE's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate XENE's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: XENE is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: XENE is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate XENE's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: XENE is good value based on its PB Ratio (2.5x) compared to the US Biotechs industry average (3.6x).
Next Steps
Future Growth
How is Xenon Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
-18.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: XENE is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: XENE is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: XENE is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: XENE's revenue (32.7% per year) is forecast to grow faster than the US market (9.3% per year).
High Growth Revenue: XENE's revenue (32.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if XENE's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Xenon Pharmaceuticals performed over the past 5 years?
-32.7%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: XENE is currently unprofitable.
Growing Profit Margin: XENE is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: XENE is unprofitable, and losses have increased over the past 5 years at a rate of -32.7% per year.
Accelerating Growth: Unable to compare XENE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: XENE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).
Return on Equity
High ROE: XENE has a negative Return on Equity (-20.08%), as it is currently unprofitable.
Next Steps
Financial Health
How is Xenon Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: XENE's short term assets ($233.9M) exceed its short term liabilities ($48.5M).
Long Term Liabilities: XENE's short term assets ($233.9M) exceed its long term liabilities ($541.0K).
Debt to Equity History and Analysis
Debt Level: XENE's debt to equity ratio (8.3%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if XENE's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: XENE has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: XENE has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 24% each year
Next Steps
Dividend
What is Xenon Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate XENE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate XENE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if XENE's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if XENE's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of XENE's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.8yrs
Average management tenure
CEO
Simon Pimstone (52yo)
17.5yrs
Tenure
US$2,612,720
Compensation
Dr. Simon N. Pimstone, M.B. ChB., Ph.D., FRCPC, M.D, is a Scientific Co-Founder of Xenon Pharmaceuticals Inc. in 1996 and has been its Chief Executive Officer since January 2003. He had served as President ...
CEO Compensation Analysis
Compensation vs Market: Simon's total compensation ($USD2.61M) is about average for companies of similar size in the US market ($USD2.15M).
Compensation vs Earnings: Simon's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 17.5yrs | US$2.61m | 0.78% $3.5m | |
| President | 2.33yrs | US$1.55m | 1.11% $5.0m | |
| Chief Medical Officer | 2.33yrs | US$1.07m | 0.13% $574.2k | |
| Vice President of Corporate Affairs & Investor Relations | 3.33yrs | no data | no data | |
| Senior Vice President of Human Resources | 0.83yr | no data | no data | |
| Executive Vice President of Strategy & Innovation | no data | US$552.84k | 0.048% $217.3k | |
| Senior Vice President of Drug Discovery | 4.42yrs | US$545.00k | no data |
2.8yrs
Average Tenure
58yo
Average Age
Experienced Management: XENE's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 17.5yrs | US$2.61m | 0.78% $3.5m | |
| Independent Director | 16.75yrs | US$142.11k | 0.17% $784.8k | |
| Independent Director | 21.33yrs | US$147.38k | 0.35% $1.6m | |
| Independent Chairman | 21.17yrs | US$169.62k | 0.20% $902.1k | |
| Independent Director | 23.67yrs | US$131.93k | 0.78% $3.5m | |
| Independent Director | 16.5yrs | US$144.74k | 0.097% $440.2k | |
| Independent Director | 0.50yr | no data | no data | |
| Independent Director | 5.17yrs | US$139.84k | 0.043% $194.1k | |
| Independent Director | 3.83yrs | US$136.08k | 0.34% $1.5m |
16.8yrs
Average Tenure
63yo
Average Age
Experienced Board: XENE's board of directors are seasoned and experienced ( 16.8 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: XENE insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 35.7%.
Top Shareholders
Company Information
Xenon Pharmaceuticals Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Xenon Pharmaceuticals Inc.
- Ticker: XENE
- Exchange: NasdaqGM
- Founded: 1996
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$452.565m
- Shares outstanding: 34.97m
- Website: https://www.xenon-pharma.com
Number of Employees
Location
- Xenon Pharmaceuticals Inc.
- 200 – 3650 Gilmore Way
- Burnaby
- British Columbia
- V5G 4W8
- Canada
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| XENE | NasdaqGM (Nasdaq Global Market) | Yes | Common Shares | US | USD | Nov 2014 |
| XP0 | DB (Deutsche Boerse AG) | Yes | Common Shares | DE | EUR | Nov 2014 |
Biography
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline include XEN496, A Kv7 potassium channel modulator that is Phase II clinical trials for the treatment of KCNQ2 epilepsy; XEN1101, A Kv7 potassium channel modulator, which is in Phase II clinical trial for the treatment of epilepsy. The company’s product candidates also comprise XEN901, a selective Nav1.6 sodium channel inhibitor that is in Phase I clinical trials for the treatment of epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase I clinical trials. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop first-in-class treatments for epilepsy. The company was founded in 1996 and is headquartered in Burnaby, Canada.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/07/02 00:06 |
| End of Day Share Price | 2020/07/01 00:00 |
| Earnings | 2020/03/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.